Method for treating pulmonary hypertension with interleukin-5 receptor antibody
AssigneesNational University Corporation University of Toyama, Kyowa Kirin Co., Ltd.
InventorsMasashi Ikutani, Kiyoshi Takatsu, Hiromi Ehara, Ikuko Fujino, Shinya Ogawa
Life of this patent
Estimating the term…
Abstract
The present invention relates to a therapeutic agent for pulmonary hypertension comprising an interleukin-5 receptor (hereinafter, abbreviated to “IL-5R”)-inhibiting compound and therapeutic method therefor. More specifically, the present invention relates to a therapeutic agent for pulmonary hypertension comprising an antibody or an antibody fragment capable of specifically binding to the extracellular region of IL-5R and a therapeutic method therefor.
Claims9
A method for treating pulmonary hypertension, comprising administering an effective amount of an antibody or an antibody fragment thereof which binds to the extracellular region of an interleukin-5 receptor (IL-5R) to inhibit an IL-5R-expressing cell,
- wherein said antibody or antibody fragment thereof comprises a heavy chain variable (VH) domain containing 3 complementarity determining regions (CDRs), and a light chain variable (VL) domain containing 3 CDRs,
- wherein the 3 CDRs on said VH domain comprise the amino acid sequences of SEQ ID NOs:
- 1-3, respectively, and the 3 CDRs on said VL domain comprise the amino acid sequences of SEQ ID NOs:
- 4-6, respectively.
Dependencies are inferred from the claim text.